This multiple sclerosis treatment stock is in a handle of a long cup base. It recently raised its 2026 revenue forecast.

Consider Teva Pharmaceutical Industries (NYSE: TEVA) the "comeback kid" among pharmaceutical stocks. As recently as a few ...

Ascentage Pharma reported 2024 sales of $134.3M, up 342% YoY, driven by a $100M option payment from Takeda under an exclusive agreement. JP Morgan initiated Ascentage Pharma with an Overweight rating ...

Pharmaceutical stocks can be excellent defensive investments during times of economic uncertainty, and many pharma stocks are ...

Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data dented their belief that the biotech can match rivals, including Johnson & ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

Pharmaceutical stocks are widely regarded for their huge potential, but they come with risks. We cover how to find the best stocks in the pharma industry.

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings.

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...